Compare Mongodb Inc (MDB) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mongodb Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? Mongodb Inc trades at $348.99 (market cap $28.70B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B). The key difference: Mongodb Inc is far larger — about 3.9× Spyre Therapeutics Inc. Common Stock's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, Mongodb Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mongodb Inc for 46 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| MDB | SYRE | |
|---|---|---|
Market Cap | $28.70B | $7.35B |
Volume | 1,357,938 | 1,624,631 |
Sector | Technology | Health |
52-Week High | $472.29 | $108.92 |
52-Week Low | $225.95 | $22.18 |
Typical Hold Time | 46 Days | 0 Days |
Enterprise Value | $26.32B | $6.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MongoDB (MDB) trades at $373.07, down 2.16% today, amid a bullish technical setup with moving averages supportive and a neutral oscillator stance. The company reported a net loss of $129.07 million in 2025, but revenue grew to $2.01 billion, with a projected return to profitability in 2026. Recent Investor Day highlighted new AI product launches and raised long-term growth targets, though the unexpected CEO departure to Meta caused volatility.
The outlook is positive with strong analyst support (80% buy ratings) and a $456.76 consensus price target implying significant upside. Key risks include execution during leadership transition and high valuation multiples. Revenue growth acceleration and AI-driven product adoption present the primary investment opportunity, balanced against competitive and macroeconomic pressures.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mongodb Inc
Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
Read more on MDB →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
